Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M375Revenue $M0.2Net Margin (%)-28,157.8Altman Z-Score9.4
Enterprise Value $M259EPS $-1.3Operating Margin %-29,637.6Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.7Pre-tax Margin (%)-28,155.1Higher ROA y-yY
Price/Book2.510-y EBITDA Growth Rate %-15.3Quick Ratio9.1Cash flow > EarningsY
Price/Sales1,1285-y EBITDA Growth Rate %-15.7Current Ratio9.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-47.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-51.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M59.5ROIC % (ttm)-371.7Gross Margin Increase y-yN

Gurus Latest Trades with ARWR

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARWRGeorge Soros 2014-06-30 Sold Out -0.01%$9.79 - $18.28
($13.09)
$ 6.30-52%Sold Out0
ARWRGeorge Soros 2014-03-31 Buy 0.01%$9.92 - $26.57
($17.36)
$ 6.30-64%New holding44,200
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARWR is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ARWR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Lewis David L.Chief Scientific Officer 2015-01-05Sell15,000$8.01-21.35 view
Anzalone Christopher RichardPresident and CEO 2014-10-15Buy16,000$6.32-0.32 view
Anzalone Christopher RichardPresident and CEO 2014-10-15Buy16,000$6.32-0.32 view
McKenney CharlesDirector 2014-10-01Sell2,500$14.7-57.14 view
Lewis David L.Chief Scientific Officer 2014-09-30Sell15,000$15.02-58.06 view
GIVEN DOUGLAS BDirector 2014-09-26Sell2,000$15.24-58.66 view
GIVEN DOUGLAS BDirector 2014-08-15Sell5,000$13.9-54.68 view
Myszkowski Kenneth AllenCFO 2014-08-15Sell40,000$14.02-55.06 view
McKenney CharlesDirector 2014-06-09Sell22,000$14.32-56.01 view
Myszkowski Kenneth AllenCFO 2014-02-12Sell16,000$18.77-66.44 view

Press Releases about ARWR :

    Quarterly/Annual Reports about ARWR:

    News about ARWR:

    Articles On GuruFocus.com
    Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
    Weekly CEO Buys Highlight: NRP, OPK, GAM, KEY, ARWR Oct 20 2014 
    Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 10 2011 
    Weekly CFO Buys Highlight: JAZZ, VRTB, ASTM, ARWR, CGX Sep 04 2010 
    Arrowhead Research Corp. Reports Operating Results (10-Q) May 13 2010 
    Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 11 2010 
    Arrowhead Research Corp. Reports Operating Results (10-K) Dec 22 2009 
    Arrowhead Research Corp. Reports Operating Results (10-Q) Aug 10 2009 
    Arrowhead Reports Third Quarter Fiscal 2009 Financial Results Aug 10 2009 
    Arrowhead Research Corp. Reports Operating Results (10-Q) May 15 2009 

    More From Other Websites
    Arrowhead to Present at Jefferies 2015 Healthcare Conference May 27 2015
    ARROWHEAD RESEARCH CORP Financials May 20 2015
    10-Q for Arrowhead Research Corp. May 13 2015
    Arrowhead Research reports 2Q loss May 11 2015
    Arrowhead Research reports 2Q loss May 11 2015
    Arrowhead Research Corp Earnings Call scheduled for 4:30 pm ET today May 11 2015
    ARROWHEAD RESEARCH CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 11 2015
    Arrowhead Reports Fiscal 2015 Second Quarter Financial Results May 11 2015
    Q2 2015 Arrowhead Research Corp Earnings Release - After Market Close May 11 2015
    Arrowhead Presents Data on Potential RNAi Candidate Targeting Factor 12 Mediated Angioedemic and... May 06 2015
    Arrowhead Completes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study... May 05 2015
    Arrowhead to Report Fiscal 2015 Second Quarter Financial Results May 04 2015
    Arrowhead Publishes Data on Advances in Subcutaneous siRNA Delivery Apr 30 2015
    Arrowhead to Present at Upcoming Conferences Apr 28 2015
    Analyst Wants Proof On Arrowhead Research's Hepatitis B Drug Apr 14 2015
    Arrowhead Research (ARWR) Stock Falls Today on Jefferies Downgrade Apr 14 2015
    Top Analyst Upgrades and Downgrades: Apple, AMC, BP, LendingClub, Monster, Seagate and More Apr 14 2015
    Alamos Gold and Perrigo are big market movers Apr 13 2015
    Arrowhead Research (ARWR) Stock Rises Today as FDA Allows Study to Proceed Apr 13 2015
    Arrowhead Cleared to Proceed with Multiple Dose Phase 2b Study of ARC-520 Apr 13 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Truthtracer@twitter
    ReplyTruthtracer@twitter - 1 year ago
    Correction, carefully read the scientific foundation shared in the 4th quarter report.
    Truthtracer@twitter
    ReplyTruthtracer@twitter - 1 year ago
    Pay attention to the science in the third quarter report. Institutional holdings have increased from 30% to over 70% in 3 months. Reputable, longer term holders...
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK